RESUMO
Amantadine (AMA) is an uncompetitive antagonist of the N-methyl-d-aspartate receptor, with clinical application, acting on treatment of influenza A virus and Parkinson's disease. It has been proposed that AMA can indirectly modulate dopaminergic transmission. In high doses, the central nervous system is its primary site of toxicity. To examine deleterious effects on CNS induced by AMA, this study evaluated possible neurobehavioral alterations induced by AMA such as stereotyped behavior, the effects on locomotion and memory and its possible genotoxic/mutagenic activities. Adult male CF-1 mice were treated with a systemic injection of AMA (15, 30 or 60 mg kg(-1) ) 20 min before behavioral tasks on open field and inhibitory avoidance. Higher AMA doses increased the latency to step-down inhibitory avoidance test in the training session in the inhibitory avoidance task. At 60 mg kg(-1) AMA induced impairing effects on locomotion and exploration and hence impaired habituation to a novel environment. Stereotyped behavior after each administration in a 3-day trial was observed, suggesting effects on dopaminergic system. Amantadine was not able to induce chromosomal mutagenesis or toxicity on bone marrow, as evaluated by the micronucleus assay. At the lowest dose tested, AMA did not induce DNA damage and it was unable to impair memory, locomotion, exploration or motivation in mice. However, higher AMA doses increased DNA damage in brain tissue, produced locomotor disturbances severe enough to preclude testing for learning and memory effects, and induced stereotypy, suggesting neurotoxicity.
Assuntos
Amantadina/toxicidade , Comportamento Animal/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Dano ao DNA , Amantadina/farmacologia , Animais , Ensaio Cometa , Dopaminérgicos/toxicidade , Habituação Psicofisiológica/efeitos dos fármacos , Masculino , Memória/efeitos dos fármacos , Camundongos , Testes para Micronúcleos , Receptores de N-Metil-D-Aspartato/antagonistas & inibidores , Comportamento Estereotipado/efeitos dos fármacosRESUMO
Pterocaulon polystachyum DC is a native species to southern Brazil, Paraguay, Uruguay and northeastern Argentina. It is utilized to treat animal problems popularly diagnosed as "mycoses". The antifungal and amebicidal activity of its hexane extract has been previously reported, although there are no studies confirming the safety of this plant for therapeutic purposes to date. Hence, this study investigates the toxic effects of a hexane extract of Pterocaulon polystachyum administered as acute and subacute oral treatments. After acute treatment the extract caused alterations in biochemical parameters, morphological alterations in tissues and was genotoxic, according to the comet assay; neither mortality nor visible signs of lethality were seen in mice. Similarly subacute treatment caused important differences in biochemical parameters and tissues, between control and treated groups. The results also revealed genotoxicity in kidney tissue, though no mutagenicity was detected by the micronucleus test. No animal died during the treatment period.
Assuntos
Antifúngicos/toxicidade , Asteraceae/toxicidade , Animais , Asteraceae/química , Comportamento Animal/efeitos dos fármacos , Análise Química do Sangue , Ensaio Cometa , Relação Dose-Resposta a Droga , Feminino , Rim/patologia , Fígado/patologia , Masculino , Camundongos , Testes de Mutagenicidade , Extratos Vegetais/toxicidade , Caracteres SexuaisRESUMO
Duloxetine is a potent inhibitor of serotonin and noradrenaline reuptake, with weak effects on dopamine reuptake, used in the treatment of major depression. It has been recognized that some antidepressants can affect memory in humans, but there is not study that report the duloxetine effect on memory using the inhibitory avoidance. The aim of this work was to investigate the effect of duloxetine on short- and long-term memory (STM and LTM) in the inhibitory avoidance task in mice. Duloxetine (10 and 20 mg/kg; i.p.) administered before or after the inhibitory avoidance training was not able to produce effects on STM e LTM (p>0.05). The group that received MK-801 (0.0625 mg/kg), an NMDA receptor antagonist, showed an impairment in STM and LTM (p<0.01). These effects were not reversed by duloxetine administration (p=0.114 and p=0.06, respectively). Duloxetine effect on memory 5 days after i.p. administration was also investigated. After this treatment both duloxetine doses used were unable to affect STM or LTM in the inhibitory avoidance task (p=0.371 and p=0.807, respectively). DNA damages were evaluated in brain tissues and blood by the comet assay, after subacute treatment (10 or 20 mg/kg by 5 days). Duloxetine did not induce genotoxic effects. However, when the cells were treated ex vivo hydrogen peroxide, a pro-oxidant effect on brain tissue from treated animals was observed with significantly higher DNA damage in comparison to untreated animals, suggesting increased susceptibility to injuries by reactive oxygen species in brain after treatment with duloxetine. Duloxetine did not produce any effect on memory after acute and subacute administration, suggesting that this antidepressant does not affect either memory acquisition or consolidation.